Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a strong sell rating to a sell rating in a report issued on Saturday.

A number of other analysts have also weighed in on AUTL. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Finally, Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Trading Down 1.9%

AUTL opened at $2.07 on Friday. The stock has a 50-day moving average of $1.59 and a 200 day moving average of $1.55. Autolus Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.52. The firm has a market cap of $550.95 million, a P/E ratio of -1.90 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. On average, research analysts forecast that Autolus Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of the business. Syncona Portfolio Ltd bought a new position in shares of Autolus Therapeutics in the 2nd quarter worth $26,625,152,000. Schroder Investment Management Group boosted its position in Autolus Therapeutics by 133.7% during the third quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after purchasing an additional 4,824,763 shares in the last quarter. Mak Capital One LLC boosted its position in Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares in the last quarter. Armistice Capital LLC boosted its position in Autolus Therapeutics by 30.0% during the third quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Autolus Therapeutics by 108.1% in the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.